EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts

Baotong Zhang, Mingcheng Liu, Fengyi Mai, Xiawei Li, Wenzhou Wang, Qingqing Huang, Xiancai Du, Weijian Ding, Yixiang Li, Benjamin G Barwick, Jianping Jenny Ni, Adeboye O Osunkoya und 4 weitere

Journal of Clinical Investigation · 15.07.2024 · 134 (14)

DOI: 10.1172/jci175949 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 23.05.2024. Verfasst von Baotong Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Cell Biology and Genetics, Southern University of Science and Technology, School of Medicine, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, PTEN Phosphohydrolase, Cancer-Associated Fibroblasts, Kruppel-Like Transcription Factors. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Natural Science Foundation of China, Department of Science and Technology of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inactivation of phosphatase and tensin homolog ( PTEN ) is prevalent in human prostate cancer and causes high-grade adenocarcinoma with a long latency. Cancer-associated fibroblasts (CAFs) play a pivotal role in tumor progression, but it remains elusive whether and how PTEN -deficient prostate cancers reprogram CAFs to overcome the barriers for tumor progression. Here, we report that PTEN deficiency induced Krüppel-like factor 5 (KLF5) acetylation and that interruption of KLF5 acetylation orchestrated intricate interactions between cancer cells and CAFs that enhance FGF receptor 1 (FGFR1) signaling and promote tumor growth. Deacetylated KLF5 promoted tumor cells to secrete TNF-α, which stimulated inflammatory CAFs to release FGF9. CX3CR1 inhibition blocked FGFR1 activation triggered by FGF9 and sensitized PTEN -deficient prostate cancer to the AKT inhibitor capivasertib. This study reveals the role of KLF5 acetylation in reprogramming CAFs and provides a rationale for combined therapies using inhibitors of AKT and CX3CR1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPTEN PhosphohydrolaseCancer-Associated FibroblastsKruppel-Like Transcription FactorsMaleHumansAcetylationAnimalsMiceCellular ReprogrammingCell Line, Tumor

Stichwörter der Autor:innen

OncologyProstate cancer

Substanzen

PTEN PhosphohydrolaseKruppel-Like Transcription FactorsKLF5 protein, humanPTEN protein, humanKlf5 protein, mousePten protein, mouse

Autor:innen und Institutionen

  • Department of Human Cell Biology and Genetics, Southern University of Science and Technology, School of Medicine, Shenzhen, Guangdong, China.
  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
  • Inner Mongolia Institute of Quality and Standardization, Inner Mongolia Administration for Market Regulation, Hohhot, China.
  • Departments of Pathology and Urology, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Key Laboratory of Major Metabolic Diseases and Nutritional Regulation of Anhui Department of Education, School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, China.

Förderung

  • NCI NIH HHS
  • National Natural Science Foundation of China
  • Department of Science and Technology of Guangdong Province
  • Science, Technology and Innovation Commission of Shenzhen Municipality
  • Guangdong Basic and Applied Basic Research Foundation
  • Department of Defense Prostate Cancer Research Program
  • Foundation for the National Institutes of Health

Zitieren

APA

Zhang, B., Liu, M., Mai, F., Li, X., Wang, W., Huang, Q., Du, X., Ding, W., Li, Y., Barwick, B. G., Ni, J. J., Osunkoya, A. O., Chen, Y., Zhou, W., Xia, S., & Dong, J. T. (2024). Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts. Journal of Clinical Investigation, 134(14). https://doi.org/10.1172/jci175949

Vancouver

Zhang B, Liu M, Mai F, Li X, Wang W, Huang Q, et al. Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts. Journal of Clinical Investigation. 2024;134(14). doi:10.1172/jci175949

BibTeX
@article{Zhang2024,
  author = {Zhang, Baotong and Liu, Mingcheng and Mai, Fengyi and Li, Xiawei and Wang, Wenzhou and Huang, Qingqing and Du, Xiancai and Ding, Weijian and Li, Yixiang and Barwick, Benjamin G and Ni, Jianping Jenny and Osunkoya, Adeboye O and Chen, Yuanli and Zhou, Wei and Xia, Siyuan and Dong, Jin-Tang},
  title = {Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  volume = {134},
  number = {14},
  doi = {10.1172/jci175949}
}
Kostenlos starten →